Phase I Study of Doxil® and Vinorelbine in Patients with Advanced Malignancies

References

• Gabizon A., Catane R., Uziely B., Kaufman B., Safra T., Cohen R., Martin F., Huang A., Barenholz Y. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res. 1994; 54: 987–992, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Northfelt D., Dezube B., Thommes J., Levine R., Von Roenn J., Dosik G., Rios A., Krown S., DuMond C., Mamelok R. Efficacy of pegylated liposomal doxorubicin in the treatment of AIDS-related Kaposi's sarcoma after failure of standard chemotherapy. J. Clin. Oncol. 1996; 15: 653–659
   Web of Science ®Google Scholar
• Northfelt D., Dezube B., Thommes J., Miller B., Fishcl M., Friedman-Kien A., Kaplan L., DuMond C., Mamelok R., Henry D. Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial. J. Clin. Oncol. 1998; 16: 2445–2451, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Harrison M., Tomlinson N., Stewart S. Liposomal-entrapped doxorubicin: an active agent in AIDS-related Kaposi's sarcoma. J. Clin. Oncol. 1995; 13(4)914–920, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Stewart S., Jablonowski H., Goebel F., Arasteh K., Spittle M., Rios A., Aboulafia D., Galleshaw J., Dezube B. Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma. J. Clin. Oncol. 1998; 16: 683–691, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Bergin C. Treatment of Kaposi's sarcoma with liposomal doxorubicin. Am. J. Health-Syst. Pharm. 1995; 52: 2001–2004
   PubMed Web of Science ®Google Scholar
• Muggia F., Hainsworth J., Jeffers S., Miller P., Groshen S., Tan M., Roman L., Uziely B., Muderspach L., Garcia A., Burnett A., Greco F., Morrow C., Paradiso L., Liang L. Phase II study of DOXIL in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. J. Clin. Oncol. 1997; 15: 987–993, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Ranson M., Carmichael J., O'Byrne K., Stewart S., Smith D., Howell A. Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase II trial. J. Clin. Oncol. 1997; 15: 3185–3191, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Working P., Newman M., Huang S., Mayhew E., Vaage J., Lasic D. Pharmacokinetics, biodistribution and therapeutic efficacy of doxorubicin encapsulated in Stealth® liposomes (Doxil®). J. Liposome Res. 1994; 4(1)667–687
   Google Scholar
• Gordon K., Tajuddin A., Guitart J., Kuzel T., Eramo L., Roenn J. Hand-foot syndrome associated with liposome-encapsulated doxorubicin therapy. Cancer 1995; 75: 2169–2173, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Ranson M., O'Byrne K., Carmichael J., Smith D., Stewart S., Howell A. Phase II Dose-Finding Trial of Dox-SL® (Stealth® Liposomal Doxorubicin HCl) in the Treatment of Advanced Breast Cancer. ASCO. 1996; 161
   Google Scholar
• Uziely B., Jeffers S., Isacson R., Kutsch K., WeiTsao D., Yehoshua Z., Libson E., Muggia F., Gabizon A. Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies. J. Clin. Oncol. 1995; 13(7)1777–1785, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Amantea M., Newman M., Sullivan T. Relationship of dose intensity to the induction of palmar-plantar erythrodysesthesia by pegylated liposomal doxorubicin in dogs. Hum. Exp. Toxicol. 1999; 18(1)17–26, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Vaage J., Colbern G., Working P. Combined Antitumor Therapy with Doxil(R) and Navelbine in HT29 Colon Xenografts. ASCO. 1998; 977
   Google Scholar
• Hoheneker J. A summary of vinorelbine (Navelbine) safety data from North American clinical trials. Semin. Oncol. 1994; 21: 42–47
   Web of Science ®Google Scholar
• Budman D., Calabro A., Wang L., Liu X., Stiel L., Kreis W., Adams L. Sequence dependent synergistic cytotoxic effects in vitro with vinorelbine and paclitaxel. Proc. AACR 1998; 39: 309, abstr # 2112
   Google Scholar
• Krikorian A. Pharmacokinetics and metabolism of navelbine ®. Semin. Oncol. 1989; 16 (2)(Supplement 4)21–25
   Google Scholar
• Havlin K., Lucas S., Guaspari A. Phase I/II Study of Daily X 3 Navelbine with an Attempt at Dose-Escalation with Filgrastim in Metastatic Breast Cancer. ASCO. 1996; 154a
   Google Scholar
• Budman D., Weiselberg L., O'Mara V. A Phase I study of sequential vinorelbine followed by paclitaxel. Ann. Oncol. 1999; 10: 861–863, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Gershenson D., Burke T., Morris M., Bast R., Guaspari A., Hohneker J., Wharton J. A phase I study of a daily X3 schedule of intravenous vinorelbine for refractory epithelial ovarian cancer. Gynecol. Oncol. 1998; 70(3)404–409, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Masters G., Hoffman P., Hsieh A., Drinkard L., Mick R., Samuels B., Guaspari A., Golomb H., Vokes E. Phase I study of vinorelbine and ifosfamide in advanced non-small-cell lung cancer. J. Clin. Oncol. 1997; 15(3)884–892, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Spiridonidis C., Laufman L., Jones J. Daily Vinorelbine-Cisplatin in Patients with Advanced Non-Small Cell Lung Cancer: A Feasibility Trial of a New Schedule. ASCO. 1997; 483a, #1738
   Google Scholar
• Spiridonidis C., Laufman L., Jones J., Rhodes V. Daily times four vinorelbine plus cisplatin in advanced non-small cell lung cancer: a phase II study of a novel schedule. Ann. Oncol. 1999; 10: 989–991, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Pereira E., Tarasiuk J., Garnier-Suillerot A. Kinetic analysis in living cells of the inhibition of the P-glycoprotein-mediated efflux of anthracyclines by vinca alkaloids. Chem. Biol. Interact. 1998; 114(1–2)61–76, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Bakker M., Groen H., Smit E. F., Smeets J., Riggi M., Postmus P. Phase I study of high-dose epirubicin and vinorelbine in previously untreated non-small-cell lung cancer stage IIIB–IV. Br. J. Cancer 1995; 72(6)1547–1550, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Peacock N., Burris H., Dieras V., Smith L., Rodriguez G., Eckardt J., Jones S., Hardy J., Hohneker J., Bigley J., Hoff D. A phase I trial of vinorelbine in combination with mitoxantrone in patients with refractory solid tumors. Invest. New Drugs 1998; 16(1)37–43, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Hochster H. Combined doxorubicin/vinorelbine (Navelbine) therapy in the treatment of advanced breast cancer. Semin. Oncol. 1995; 22(2 Suppl. 5)55–59, discussion 59–60.[PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Llombart-Cussac A., Pivot X., Rhor-Alvarado A., Cesne A., Chevalier T., Tursz T., Spielman M. First-line vinorelbine-mitoxantrone combination in metastatic bresat cancer patients relapsing after an adjuvant anthracycline regimen: results of a phase II study. Oncology 1998; 55(5)384–390, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Pronzato P., Tognoni A., Pensa F., Vaira F., Vigani A. A dose finding study for the combination of epidoxorubicin and vinorelbine, delivered every two weeks with G-CSF support, in advanced breast cancer. J. Chemother. 1998; 10(4)326–330, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Ramirez M., Marcom P., Sutton L., Harris L., Petros W., Berry D., Warmuth M., Winer E. A Phase I/II Study of Doxil and VNB in Metastatic Breast Cancer Patients. ASCO. 1998; 650
   Google Scholar
• Gridelli C., De Placido S., Pepe R., Incoronato P., Airoma G., Rossi A., Palazzolo G., Bianco A. Phase I study of epirubicin plus vinorelbine with or without G-CSF in advanced non-small cell lung cancer. Eur. J. Cancer 1993; 12(31)1729–1731, [CROSSREF]
   Google Scholar
• Baldini E., Tibaldi C., Chiavacci F., Lieto M. D., Fioretto L., Giallom-bardo A., Taviani R., Ghezzi P., Bolognini A., Conte P. Epirubicin/vinorelbine as first line therapy in metastatic breast cancer. Breast Cancer Res. Treat. 1998; 49(2)129–134, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Blomqvist C., Hietanen P., Teerenhovi L., Rissanen P. Vinorelbine and epirubicin in metastatic breast cancer. A dose finding study. Eur. J. Cancer 1995; 31A(13–14)2406–2408, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Mathe G., Reizenstein P. Phase I pharmacologic study of a new vinca alkaloid: navelbine. Cancer Lett. 1985; 27: 285–293, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• de Jongh D., Wade J., Finley R., Joshi J., Aisner J., Wiernik P., Schimpff S. Trimethoprim/sulfamethoxazole versus placebo: a double-blind comparison of infection prophylaxis in patients with small cell carcinoma of the lung. J. Clin. Oncol. 1983; 1(5)302–307, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• National Cancer Institute Common Toxicity Criteria Document. 1999, http://ctep.cancer.gov/reporting/ctc.html
   Google Scholar
• Miller A., Hoogstraten B., Staquet M. Reporting of cancer treatment. Cancer 1981; 47: 207–214, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Jahanzeb M., Hirsch R. Phase I study of Doxil (R) in combination with escalating doses of Navelbine (R) for the treatment of patients with advanced malignancies. ASCO, asco. ASCO, Atlanta 1999; 827
   Google Scholar
• Gebbia V., Mauceri G., Fallica G. Pegylated liposomal doxorubicin with escalating dose vinorelbine in metastatic breast carcinoma: a dose finding study. ASCO. ASCO, Atlanta 1999; 811
   Google Scholar
• Burstein H., Ramirez M., Petros W. Phase I study of Doxil and vinorelbine in metastatic breast cancer. Ann. Oncol. 1999; 10(9)1113–1116, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Hoff P., Valero V., Ibrahim N., Willey J., Hortobagyi G. Hand-foot syndrome following prolonged infusion of high doses of vinorelbine. Cancer 1998; 82(5)965–969, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Kouroukis C., Hings I. Respiratory failure following vinorelbine tartrate infusion in a patient with non-small cell lung cancer. Chest 1997; 112(3)846–848, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar